SOUTH SAN FRANCISCO, Calif., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that it will host a Research and Development Day focusing on the Company’s Factor VIIa and Factor IX hemophilia programs on Tuesday, December 18, from 12:00-2:00 p.m. EST at the Lotte New York Palace.
Catalyst Biosciences' management team will provide an update on the Company’s ongoing clinical development work with marzeptacog alfa (activated) (MarzAA), a high potency engineered Factor VIIa for the potential subcutaneous prophylactic treatment of hemophilia A or B with inhibitors, and Factor IX, dalcinonacog alfa (DalcA, formerly known as CB 2679d/ISU304) for the potential subcutaneous prophylactic treatment of hemophilia B. The Company recently announced updated positive interim data from its Phase 2/3 study of MarzAA, which was presented at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition on December 1, 2018.
This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. For those who are unable to attend in person, a live webcast and replay of the event will be accessible here. If you would like to ask a question during the live Q&A portion of the event, please submit your request via email.
About Catalyst Biosciences
Catalyst is a clinical-stage biopharmaceutical company developing novel medicines to address hematology indications. Catalyst is focused on the field of hemostasis, including the subcutaneous prophylaxis of hemophilia and facilitating surgery in individuals with hemophilia. For more information, please visit www.catalystbiosciences.com.
This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements about the potential for marzeptacog alfa (activated) (MarzAA) to provide prophylaxis therapy in patients with hemophilia A or B with inhibitors, and for dalcinonacog alfa (DalcA, formerly known as CB 2679d/ISU304) to provide phophylaxis therapy in patients with hemophilia B. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that the Company makes, including, but not limited to, the risk that trials and studies may be delayed and may not have satisfactory outcomes, that additional human trials will not replicate the results from earlier trials, that potential adverse effects may arise from the testing or use of MarzAA or DalcA, including the generation of antibodies, which has been observed in patients treated with DalcA, the risk that costs required to develop or manufacture the Company’s products will be higher than anticipated, competition and other factors that affect our ability to establish collaborations on commercially reasonable terms and other risks described in the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 filed with the Securities and Exchange Commission on November 1, 2018, and with other filings with the Securities and Exchange Commission. The Company does not assume any obligation to update any forward-looking statements, except as required by law.
Fletcher Payne, CFO
Catalyst Biosciences, Inc.
Josephine Belluardo, Ph.D.
LifeSci Public Relations